|
1
|
Alekseeva NA, Streltsova MA, Vavilova JD, Ustiuzhanina MO, Palamarchuk AI, Boyko AA, Timofeev ND, Popodko AI, Kovalenko EI. Obtaining Gene-Modified HLA-E-Expressing Feeder Cells for Stimulation of Natural Killer Cells. Pharmaceutics 2024; 16:133. [PMID: 38276503 PMCID: PMC10818548 DOI: 10.3390/pharmaceutics16010133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 12/30/2023] [Accepted: 01/16/2024] [Indexed: 01/27/2024] Open
Abstract
Human cytomegalovirus (HCMV)-specific adaptive NK cells are capable of recognizing viral peptides presented by HLA-E on infected cells via the NKG2C receptor. Using retroviral transduction, we have generated a K562-cell-based line expressing HLA-E in the presence of the HLA-E-stabilizing peptide, which has previously shown the capacity to enhance adaptive NK cell response. The obtained K562-21E cell line was employed to investigate proliferative responses of the CD57- NK cell subset of HCMV-seropositive and seronegative donors. Stimulation of CD57- NK cells with K562-21E/peptide resulted in an increased cell expansion during the 12-day culturing period, regardless of the serological HCMV status of the donor. The enhanced proliferation in response to the peptide was associated with a greater proportion of CD56brightHLA-DR+ NK cells. In later stages of cultivation, the greatest proliferative response to K562-21E/peptide was shown for a highly HCMV-seropositive donor. These expanded NK cells were characterized by the accumulation of CD57-KIR2DL2/3+NKG2C+NKG2A- cells, which are hypothesized to represent adaptive NK cell progenitors. The K562-21E feeder cells can be applied both for the accumulation of NK cells as therapeutic effectors, and for the study of NK cell maturation into the adaptive state after the HLA-E peptide presentation.
Collapse
Affiliation(s)
- Nadezhda A. Alekseeva
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia; (N.A.A.); (M.A.S.); (J.D.V.); (M.O.U.); (A.I.P.); (A.A.B.); (N.D.T.)
| | - Maria A. Streltsova
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia; (N.A.A.); (M.A.S.); (J.D.V.); (M.O.U.); (A.I.P.); (A.A.B.); (N.D.T.)
| | - Julia D. Vavilova
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia; (N.A.A.); (M.A.S.); (J.D.V.); (M.O.U.); (A.I.P.); (A.A.B.); (N.D.T.)
| | - Maria O. Ustiuzhanina
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia; (N.A.A.); (M.A.S.); (J.D.V.); (M.O.U.); (A.I.P.); (A.A.B.); (N.D.T.)
| | - Anastasia I. Palamarchuk
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia; (N.A.A.); (M.A.S.); (J.D.V.); (M.O.U.); (A.I.P.); (A.A.B.); (N.D.T.)
| | - Anna A. Boyko
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia; (N.A.A.); (M.A.S.); (J.D.V.); (M.O.U.); (A.I.P.); (A.A.B.); (N.D.T.)
| | - Nikita D. Timofeev
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia; (N.A.A.); (M.A.S.); (J.D.V.); (M.O.U.); (A.I.P.); (A.A.B.); (N.D.T.)
| | - Alexey I. Popodko
- Department of Radiation Oncology, European Medical Center, Schepkina 35, 129110 Moscow, Russia;
| | - Elena I. Kovalenko
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia; (N.A.A.); (M.A.S.); (J.D.V.); (M.O.U.); (A.I.P.); (A.A.B.); (N.D.T.)
| |
Collapse
|